Texas Supplement Brands, the FDA Just Redrew the Map

What the agency's 2026 ingredient rulemaking push means for your business and your labels

The FDA Is Asking a Deceptively Simple Question

What exactly is a dietary ingredient? You would think that after more than 30 years under the Dietary Supplement Health and Education Act (DSHEA), we would have a clean answer to that. We do not. And the FDA is now making it official that the ambiguity has to go.

In March 2026, the FDA held a public meeting titled "Exploring the Scope of Dietary

Supplement Ingredients," convening its Office of Dietary Supplement Programs (ODSP) alongside industry, academia, and trade associations to hash out how emerging ingredient types like lab-grown proteins, enzymes, and microbials fit within the dietary supplement framework.

If your product contains a novel ingredient or one produced using new manufacturing methods, this rulemaking process directly affects whether it can legally stay on the market.

The meeting opened a public comment docket (FDA-2026-N-2047) and will inform the FDA's next steps on ingredient classifications. That is regulatory shorthand for: rules are coming, and the window to influence them is open right now.

Meanwhile, Your Labels Might Already Be Wrong

Separate from the ingredient scope question, the FDA quietly signaled a labeling shift in December 2025 that every Texas supplement brand should know about.

Under current regulations, if a dietary supplement makes a structure/function claim such as "supports immune health" or "promotes healthy joints," the required DSHEA disclaimer must appear on every panel of the product label where that claim appears. The FDA has been enforcing this for years.

In a letter to the dietary supplement industry, the FDA announced it intends to exercise enforcement discretion on the multi-panel disclaimer requirement while it considers revising the rule. In plain terms, the agency will not currently penalize brands for having the disclaimer on only one panel rather than every panel where a claim appears.

You can read the FDA's letter directly at FDA.gov.

This is not a green light to ignore labeling requirements altogether. The disclaimer still must appear on the label and must still be linked to each claim. The multi-panel placement rule is simply not being actively enforced while rulemaking is pending.

What This Means If You Sell Supplements in Texas

Texas has a large and growing dietary supplement market, with manufacturers, distributors, and retailers across Houston, Dallas, Austin, and San Antonio. Federal FDA rules apply uniformly, meaning there is no Texas exception and no grace period based on geography.

The two developments above create a specific compliance window you should be taking advantage of right now:

First, if your products contain novel ingredients, non-traditional proteins, enzymes, or microbials, the FDA's public rulemaking process is actively seeking industry input. This is a rare opportunity to help shape the definitions that will govern your products for the next decade.

Second, if your labels have been flagged or you have received demand letters related to the multi-panel disclaimer, the enforcement discretion announcement may provide near-term relief. But do not confuse temporary enforcement discretion with a permanent fix. Rulemaking can move in either direction.

The cost of getting ahead of FDA rulemaking is a fraction of the cost of responding to a warning letter after the fact.

The Bottom Line

The FDA is actively reshaping the regulatory framework for dietary supplements in 2026, from ingredient definitions to labeling requirements. Texas businesses operating in this space need to be paying attention and documenting their compliance positions now, before these proceedings close.

If you have questions about how the FDA's dietary supplement rulemaking affects your products or your label claims, the attorneys at Bustos Law Group can help you assess your risk and build a compliance strategy that holds up.

Sources: U.S. Food and Drug Administration (FDA.gov) | Haynes Boone HB At The Counter

This blog is for informational purposes only and does not constitute legal advice. For guidance specific to your business, contact Bustos Law Group.